Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
BLOOD CANCER JOURNAL（2018）
关键词
Acute lymphocytic leukaemia,Drug development,Biomedicine,general,Cancer Research,Oncology,Hematology
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要